+61.2%
IONQ vs MRNA
+153.9%
-92.7%
-74.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -8.8% | -2.2% | -6.6% | -8.6% |
| 7D | -28.3% | -12.7% | -15.6% | -27.3% |
| 30D | -35.8% | -20.7% | -15.1% | -34.3% |
| 3M | -50.1% | +46.3% | -96.4% | -51.7% |
| 6M | -60.5% | +305.2% | -365.7% | -69.7% |
| YTD | -53.8% | +561.2% | -615.1% | -70.2% |
| 1Y | -49.5% | +772.1% | -821.6% | -70.2% |
| 3Y | +61.2% | +147.0% | -85.7% | +10.7% |
| All | +61.2% | +153.9% | -92.7% | +10.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling